Clinical features and outcomes of patients with acute myeloid leukemia: the single-center experience of 668 patients in China

References

• Willier S, Rothämel P, Hastreiter M, et al. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Blood. 2021;137(8):1037–1049.
   PubMed Web of Science ®Google Scholar
• Katagiri T, Ushiki T, Masuko M, et al. Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: a case report and literature review. Medicine (Baltimore). 2017;96(36):e7975.
   PubMed Web of Science ®Google Scholar
• Harada K, Doki N, Hagino T, et al. Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. Ann Hematol. 2018;97(1):73–81.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Lachowiez CA, Takahashi K, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol: Official J Am Soc Clin Oncol. 2021;39(25):2768–2778.
   PubMed Web of Science ®Google Scholar
• Xiang HL, Chen Y, Wang JW, et al. Enhancing cytotoxicity of daunorubicin on drug-resistant leukaemia cells with microparticle-mediated drug delivery system. J Microencapsul. 2019;36(3):291–304.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Yang D, Aribi A, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018;103(9):e404–e407. doi:10.3324/haematol.2018.188094
   PubMed Web of Science ®Google Scholar
• Xu L, Chen H, Chen J, et al. Thrombospondin-2 promotes prostate cancer bone metastasis by the up-regulation of matrix metalloproteinase-2 through down-regulating miR-376c expression. J Hematol Oncol. 2017;10(1):33, doi:10.1186/s13045-017-0390-6
   PubMedGoogle Scholar
• Heuser M, Freeman SD, Ossenkoppele GJ, et al. Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138(26):2753–2767.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Pogosova-Agadjanyan EL, Moseley A, Othus M, et al. AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report. Biomark Res. 2020;8:29.
   PubMed Web of Science ®Google Scholar
• Mrózek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, Metzeler KH, Schwind S, Wu YZ, Kohlschmidt J et al: Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol: Official J Am Soc Clin Oncol. 2012, 30(36):4515-4523.
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1302–1311. doi:10.1182/blood.V98.5.1302
   PubMed Web of Science ®Google Scholar
• Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–1924.
   PubMed Web of Science ®Google Scholar
• Devine SM, Owzar K, Blum W, et al. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from cancer and leukemia group B 100103 (alliance for clinical trials in oncology)/blood and marrow transplant clinical trial network 0502. J Clin Oncol: Official J Am Soc Clin Oncol. 2015;33(35):4167–4175. doi:10.1200/JCO.2015.62.7273
   PubMed Web of Science ®Google Scholar
• Ustun C, Le-Rademacher J, Wang HL, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019;33(11):2599–2609.
   PubMed Web of Science ®Google Scholar
• Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981;58(6):1203–1212. doi:10.1182/blood.V58.6.1203.1203
   PubMed Web of Science ®Google Scholar
• Yates JW, Wallace HJ, Jr., Ellison RR, et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57(4):485–488.
   PubMedGoogle Scholar
• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53–61.
   PubMed Web of Science ®Google Scholar
• Hou HY, Lu WW, Wu KY, et al. Idarubicin is a broad-spectrum enterovirus replication inhibitor that selectively targets the virus internal ribosomal entry site. J Gen Virol 2016;97(5):1122–1133. doi:10.1099/jgv.0.000431
   PubMedGoogle Scholar
• Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol: Official J Am Soc Clin Oncol. 2010;28(5):808–814. doi:10.1200/JCO.2009.23.2652
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim H, Joo YD, et al. Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia. J Clin Oncol: Official J Am Soc Clin Oncol. 2017;35(24):2754–2763. doi:10.1200/JCO.2017.72.8618
   PubMed Web of Science ®Google Scholar
• Press RD, Eickelberg G, Froman A, et al. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse. Am J Hematol 2019;94(8):902–912.
   PubMed Web of Science ®Google Scholar
• Dillon R, Hills R, Freeman S, et al. Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood. 2020;135(9):680–688. doi:10.1182/blood.2019002959
   PubMed Web of Science ®Google Scholar